Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of Leuco-methylthioninium bis(hydromethanesulfonate) TRx0237 in Subjects With Mild Alzheimer's Disease.

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of Leuco-methylthioninium bis(hydromethanesulfonate) TRx0237 in Subjects With Mild Alzheimer's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2016

At a glance

  • Drugs TRx 0237 (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors TauRx Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Dec 2016 Results published in a TauRx Pharmaceuticals media release.
    • 17 Dec 2016 According to a TauRx Pharmaceuticals media release, top-line results from the study, were presented on 8 th December at the 9th Clinical Trials on Alzheimer's Disease (CTAD) 2016 meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top